You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Zydus Lifesciences reported second-quarter revenues of ₹79.1 billion, up 29% year-on-year, and a 24% EBITDA margin. It expects a March Saroglitazar launch and maintained full-year EBITDA margin guidance of 24%.
Illustrative technical + ownership context — a signal mix, not investment advice.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| XNSE:ZYDUSLIFE | -0.7% | +4.4% | +14.5% | -4.5% | +30.1% |
Share classes and depositary receipts can have different prices and dividends.
| Ex-dividend date | Amount per share |
|---|---|
| 2026-07-24 | 1.00 INR |
| 2025-07-25 | 11.00 INR |
| 2024-07-26 | 3.00 INR |
| 2023-07-28 | 6.00 INR |
| 2022-07-28 | 2.50 INR |
| 2021-07-28 | 3.50 INR |
| 2020-03-23 | 3.50 INR |
| 2019-07-25 | 3.50 INR |
| 2018-07-31 | 3.50 INR |
| 2017-03-16 | 3.20 INR |
| 2016-03-17 | 3.20 INR |
| 2015-07-30 | 2.40 INR |
| 2014-07-17 | 1.80 INR |
| 2013-06-11 | 1.50 INR |
| 2012-07-26 | 1.50 INR |
| 2011-07-07 | 1.25 INR |
| 2010-07-15 | 1.00 INR |
No upcoming investor events are listed for this company yet.
